Douglas Laidlaw
About Douglas Laidlaw
Douglas Laidlaw serves as the Director of Portfolio Finance and Finance Planning Systems at BridgeBio in San Francisco, California, a position he has held since 2021. He has extensive experience in finance, having previously worked at companies such as Novartis, Alcatel-Lucent, and Genentech.
Work at BridgeBio
Douglas Laidlaw has been serving as the Director of Portfolio Finance and Finance Planning Systems at BridgeBio since 2021. In this role, he is responsible for overseeing financial strategies and planning systems within the organization. His tenure at BridgeBio spans three years, during which he has contributed to the financial management and operational efficiency of the company based in San Francisco, California.
Previous Experience in Finance
Prior to joining BridgeBio, Douglas Laidlaw held various finance positions. He worked as a Finance Manager at Novartis from 2001 to 2004, where he gained experience in financial management in East Hanover, NJ. Following this, he served as a Senior Financial Analyst at Alcatel-Lucent from 1996 to 2001 in Warren, NJ. Most recently, he was a Senior Financial Manager at Genentech from 2007 to 2021, contributing to financial strategies in South San Francisco.
Education and Expertise
Douglas Laidlaw holds a Bachelor of Science (BS) degree in Business Administration and Management from The College of New Jersey, which he attended from 1992 to 1996. He furthered his education by obtaining a Master of Business Administration (MBA) with a focus on Marketing and Supply Chain Management from Rutgers Business School, completing his studies from 1999 to 2003. His educational background supports his expertise in finance and management.
Career Timeline
Douglas Laidlaw's career in finance spans several notable positions. He began as a Senior Financial Analyst at Alcatel-Lucent from 1996 to 2001, followed by a role as Finance Manager at Novartis from 2001 to 2004. After a brief period, he joined Genentech as a Senior Financial Manager from 2007 to 2021. In 2021, he transitioned to BridgeBio, where he currently holds a director position.